Stratagene Settles Litigation and Strengthens Patent Portfolio; Recent Settlement Expands Patent Portfolio for Polymerases and

Stratagene Corporation (Nasdaq:STGN), a developer,
manufacturer and marketer of specialized life science research and
diagnostic products, has recently settled litigation and significantly
strengthened its patent portfolio pertaining to proprietary enzyme
blends.
   "We are very pleased with the outcome of our settlement agreement
with Takara Bio Inc. as it significantly strengthens our patent
position in PCR technology," said Joseph A. Sorge, M.D., President and
CEO of Stratagene. "We believe that there are a number of competitors
selling products that are covered under our patent portfolio. It is
our intention to make limited licenses available and recognize
resulting licensing revenue. We believe that the opportunities created
by this settlement illustrate the inherent value of our intellectual
property and our investment in protecting our proprietary technology."
   On May 11, 2006, Stratagene announced that it had entered into a
definitive settlement agreement with Takara Bio Inc. to resolve the
companies' patent disputes in the field of enzyme blends that are
widely used in polymerase chain reaction (PCR) technology. PCR
technology allows users to amplify a small amount of DNA, making
analysis much easier and is commonly used in both research and
molecular diagnostics, including the detection of diseases such as
cancer, heart disease, AIDS, viral hepatitis, and other infectious
diseases, as well as paternity and forensic testing.
   As a result of the settlement, all pending patent litigation in
the U.S. District Court for the District of Maryland and actual and
potential patent interference proceedings in the U.S. Patent &
Trademark Office have been resolved. Potential disputes in the future
will be avoided through cross-licenses of the parties' respective
patent rights relating to enzyme blends.
   Stratagene will now own a broad U.S. patent portfolio covering its
proprietary enzyme blends. Stratagene will seek to establish a
licensing program for competitors' products covered by its broad
portfolio.

   About Stratagene Corporation

   Stratagene is a developer, marketer and manufacturer of
specialized life science research and diagnostic products. The
Company's life science research unit supports advances in science by
inventing, manufacturing and distributing products that simplify,
accelerate and improve research. These products are used throughout
the academic, industrial and government research sectors in fields
spanning molecular biology, genomics, proteomics, drug discovery and
toxicology. The Company's diagnostic unit develops and manufactures
products for urinalysis, and high quality automated instrument and
reagent systems that use blood samples to test for more than 1,000
different allergies and autoimmune disorders. In addition, by
combining its expertise in diagnostics and molecular biology, as well
as its experience with FDA regulatory procedures, the Company is
pursuing opportunities to expand its product portfolio to include
molecular diagnostic kits and instrumentation. More information is
available at www.stratagene.com.

   Safe Harbor Statement

   Certain statements in this news release that are not historical
fact constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Stockholders and
other readers are cautioned not to place undue reliance on these
forward-looking statements. Stratagene generally identifies
forward-looking statements by using words like "believe," "intend,"
"target," "expect," "estimate," "may," "should," "plan," "project,"
"contemplate," "anticipate," "predict" or similar expressions. You can
also identify forward-looking statements by discussions of strategies,
plans or intentions. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors, which may cause the
actual results of Stratagene to be materially different from
historical results or from any results expressed or implied by such
forward-looking statements. Among the important factors that could
cause actual results to differ materially from those contained in or
implied by the forward-looking statements are risks associated with
the company's inability to sufficiently anticipate market needs and
develop products and product enhancements that achieve market
acceptance, the company's ability to compete effectively in the
diagnostics and life science research markets, variability of the
company's quarterly revenues and operating results, the failure of the
company to retain key employees, the company's ability to obtain
additional debt or equity financing, the possibility of declining
sales due in part to a reduction in research and development budgets
or government funding, the company's ongoing ability to protect its
own intellectual property rights and to avoid violating the
intellectual property rights of third parties, extended manufacturing
difficulties and currency fluctuations. For more information about
these and other factors that could cause actual results to differ
materially from those contained in or implied by the forward-looking
statements please see Item "1A. Risk Factors" included in Stratagene's
Annual Report on Form 10-K for the year ended December 31, 2005 and in
other reports filed by Stratagene from time to time with the
Securities and Exchange Commission, including Quarterly Reports on
Form 10-Q.